Arginine-Vasopressin Receptor Antagonists: A New Hope for Treatment of Hyponatremia in Patients with Heart Failure
Journal Title: Indonesian Journal of Clinical Pharmacy - Year 2015, Vol 4, Issue 2
Abstract
Hyponatremia is an important problem in patients with heart failure. It has also been known as a predictor both of short and long-term clinical outcome of heart failure patients. While evidences of clinical efficacy and safety of conventional options for treatment of hyponatremia resulted from clinical trials are very limited, several clinical trials have been conducted to evaluate the efficacy and safety of arginine vasopressin antagonists or also known as vaptan group. This paper reviews hyponatremia in patients with heart failure and the important roles of arginine vasopressin in its development, pharmacological aspects and clinical trials outcomes of some vaptans and several questions emerged from those clinical trials. Relevant research papers, reviews, and website information have been searched and included in this review using keyword of heart failure, hyponatremia, arginine-vasopressin, arginine-vasopressin receptor antagonist and vaptan. Generally, clinical trials have highlighted the efficacy and safety of vaptan groups in the management of hypervolemic hyponatremia in patients with heart failure. Those drugs can effectively increase serum sodium level with tolerable adverse reactions. Based on those clinical data two drugs of vaptan group, conivaptan and tolvaptan, have been approved by Food and Drug Administration in The United States to be used for the treatment of euvolemic and hypervolemic hyponatremia. However, many experts are still hesitant to recommend vaptans as treatment of choice for hyponatremia due to the lack of patients-focused outcomes measurements.
Authors and Affiliations
Saepudin Saepudin
Keywords
Related Articles
- EP ID EP355567
- DOI 10.15416/ijcp.2015.4.2.129
- Views 101
- Downloads 0
Gene blaCTX‑M Mutation as Risk Factor of Antibiotic Resistance
Currently there are more than half from all antibiotics used in the world which is belong to β lactam group, but clinical effectiveness of the antibiotics are limited by antibiotic resistance of microorganisms as causati...
PlGF/sFlt‑1 as Early Detection Biomarker for Preeclampsia
target, particularly improving maternal health and lowering maternal mortality until one-fourth of population from 1990 until 2015. Then, this program was continued through Sustainable Development Goals (SDGs) in 2015 wi...
An Urinary Excretion Profile of 500 mg Ascorbic Acid in Healthy Adults
High doses of ascorbic acid have been commercially available as adjuvant. However, the pharmacological importance of this supplement is yet questionable. The aim of this study is to investigate the 24 hours excretion pro...
Comparison of Pharmacokinetics Profiles 0.5% Bupivacaine of Normal Pregnant Patients and Preeclampsia Patients Undergoing Sectio Caesarea at dr. Sardjito Hospital Yogyakarta
In preeclampsia pregnancy, there is a decrease in glomerular filtration and plasma protein. This study was conducted on 5 patients with normotensive pregnancy and sectio caesarea with preeclampsia pregnancy used of bupiv...
Monitoring Use of Antibiotics with ATC/DDD and DU90% Method in Abepura Hospital Jayapura, Indonesia
The high use of antibiotics will increase its irrational use, affect the mortality rates, costs and resistance, especially in a hospital. We conducted an observational study with retrospective data to evaluate the use of...